Blackfrog Averting Vaccine Wastage Via Portable Solutions

Blackfrog Technologies Pvt. Ltd., founded in 2015 and headquartered in Manipal, Karnataka, is an Indian healthcare technology company focused on strengthening immunization supply chains. The company designs and deploys precision cold-chain and vaccine traceability solutions, with a clear emphasis on improving last-mile delivery in remote and underserved regions. At the center of its portfolio is Emvolio, a patented, portable, battery-powered refrigeration system that ensures stringent temperature control for vaccines and biologicals during transit. Equipped with continuous monitoring and end-to-end traceability, Emvolio directly addresses one of the most persistent challenges in global immunization: temperature excursions and preventable wastage.

Certified under ISO 13485, Blackfrog has built its innovations on robust quality and regulatory foundations. The company has also secured support from BIRAC, C-CAMP, Venture Center, and leading impact investors, reinforcing both its technical credibility and its mission-driven approach. Collectively, Blackfrog’s solutions aim to significantly reduce vaccine wastage while enabling safer, more reliable healthcare logistics across India and international markets.

In an exclusive interaction with The Interview World at Medical Fair India 2026, Niharika Chunduri, Vice President–Business Development at Blackfrog Technologies, offers a deep dive into the company’s latest medtech innovations and their clinical relevance. She details the range of biological samples that can be safely transported using the battery-powered refrigeration system, explains the company’s pricing framework and active markets, outlines forthcoming product innovations, and articulates a clear, long-term strategy for market expansion.

The following are the key takeaways from this insightful and forward-looking conversation.

Q: Could you elaborate on your latest medtech innovations and their intended clinical applications?

A: Blackfrog Technologies has engineered Emvólio, a portable, temperature-regulated carrier purpose-built for the safe transport of biologicals. This solution functions as a compact, battery-powered refrigerator capable of operating across a wide thermal range, from –20°C to +25°C, while its primary application remains within the critical 2°C to 8°C window required for vaccines and sensitive biological samples.

Unlike passive carriers such as ice boxes or gel packs, Emvólio delivers precise and continuous temperature control. Passive systems inherently lack regulation, exposing samples to repeated freezing and thawing cycles that compromise stability and performance. In contrast, Emvólio actively maintains the user-defined temperature throughout transit.

As a result, the integrity, potency, and efficacy of vaccines and medicines remain fully preserved. This ability to ensure thermal stability, without fluctuation, represents a decisive advantage and positions Emvólio as a superior solution for last-mile biological transport.

Q: What types of samples can be stored in this battery-powered refrigerator, and for how long can each be safely maintained?

A: Emvólio supports the safe transport of a wide range of temperature-sensitive materials, including vaccines, pharmaceutical formulations, blood, and other critical biological samples. As a result, it serves diverse clinical, diagnostic, and public health use cases across the healthcare ecosystem.

Blackfrog’s flagship model, Emvólio Plus, delivers robust performance even under extreme environmental conditions. At an ambient temperature of 43°C, the system provides more than 12 hours of uninterrupted battery-backed operation. Under relatively moderate conditions of around 34°C, however, its endurance extends significantly, sustaining stable temperature control for approximately 24 to 30 hours. This reliability under heat stress underscores Emvólio Plus’s suitability for last-mile delivery in challenging geographies.

Q: What pricing model are you using for this product?

A: The maximum retail price of the product, inclusive of GST, is ₹2,66,000. While we extend selective discounts depending on the engagement, this figure represents the upper price limit.

Q: Is this product currently being sold only in India, or is it available in international markets as well?

A: Blackfrog Technologies primarily operates in India, where it works closely with multiple state governments. The company has active installations across the Northeast, as well as in key states such as Maharashtra and Karnataka. At the same time, it maintains a strong presence in the private sector, collaborating with biopharmaceutical companies and leading research institutions.

Beyond India, Blackfrog has extended its footprint internationally. The company has deployed installations and is currently running pilot programs across Africa, including Kenya and Nigeria, thereby validating its solutions in diverse and demanding healthcare environments.

Q: Which major innovations are you prioritizing over the next five to ten years?

A: Beyond its core product line, Blackfrog Technologies has recently expanded its portfolio with the launch of Emon, a dedicated temperature-monitoring device introduced just a few months ago. This solution can be retrofitted onto existing refrigerators, enabling real-time surveillance and instant alerts whenever temperatures deviate from the prescribed range.

More importantly, this platform introduces a significant technological advancement. One of its variants continuously tracks compressor health and applies predictive analytics to detect early signs of failure. As a result, users receive advance warnings well before a breakdown occurs, allowing for timely intervention and preventing costly disruptions. In parallel, Blackfrog is developing multiple device configurations and sizes to address varied operational requirements across healthcare and life sciences environments.

Q: The Government of India has launched several policies and initiatives for the medtech sector. Are you currently benefiting from any government incentives or support?

A: Now a decade into its journey, Blackfrog Technologies has benefited significantly from strong institutional and ecosystem support during its formative years. In the early stages, the company received substantial backing through grants from the Biotechnology Industry Research Assistance Council (BIRAC), which played a critical role in accelerating product development and validation. Equally important, the founders and core development team drew deep value from the broader innovation ecosystem that surrounded them.

In parallel, Blackfrog gained structured incubation and mentorship support from leading institutions, including the Venture Center in Pune and the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru. Collectively, these platforms, and the government-led innovation framework underpinning them, have contributed meaningfully to the company’s growth by providing capital access, technical guidance, and a collaborative environment conducive to deep-tech innovation.

Q: What is your long-term market expansion strategy?

A: At present, Blackfrog Technologies maintains a strong footprint within the government sector. However, the company is deliberately expanding its presence across the private healthcare ecosystem, including hospitals, diagnostic laboratories, and pharmaceutical companies. In parallel, Blackfrog is actively exploring opportunities beyond India, with a clear intent to scale its solutions across international markets.